Latticon Antibody Therapeutics, Inc.

708 Quince Orchard Rd, Ste 250-A
Gaithersburg MD 20878

Latticon Antibody Therapeutics (LAT) is a science-driven biotech company dedicated to the discovery and global development of first-in-class biological therapeutics for the treatment of cancer, cardiovascular and autoimmune diseases. Our mission is to use innovative concept and cutting-edge technology to develop novel antibody-based therapeutics which will improve disease burden and quality of life to patients with significant unmet medical needs.

LAT is a wholly-owned subsidiary of Latticon Biopharmaceuticals (LB), a China-based biopharmaceutical company founded in November 2020. LB and LAT aim to establish pioneering research and development programs covering the discovery, design and preclinical development of biologic therapeutics to address high unmet medical needs. LAT will be receiving oversea direct investment (ODI) funds from LB; and LAT’s operation cost is estimated to be ~$2M for the first two years. 

LAT is located in Gaithersburg, in the Montgomery County of Maryland, a center for biotech and life sciences with over 300 biotech companies such as AstraZeneca PLC and GlaxoSmithKline PLC, major biomedical research institutions including Johns Hopkins University and the Howard Hughes Medical Institute (HHMI), and federal government agencies including the National Institutes of Health (NIH) and the Food and Drug Administration (FDA).

LAT is founded by Dr. John Y. Li. John has over 20 years of biologics therapeutic development and IND filing experience, and extensive expertise in immuno-oncology, cardiovascular and respiratory biology. John is a primary inventor of many US patents, authors of many peer-reviewed high-impact publications and recipient of many honors and awards. Before founding LAT, John was a scientific leader at Tanox, Inc./Genentech, Inc., GlaxoSmithKline PLC and MedImmune LLC/AstraZeneca PLC, and founder and CEO of Salubris Biotherapeutics, Inc. 

LAT will have 3 full-time employees for the first two years. LAT plans to collaborate with local and international research institutions, biotech and CRO companies to advance its first-in-class therapeutic programs and preclinical studies. The long-term goal of the company is to establish a leading position in the development of innovative biologic therapeutics that will benefit patients worldwide.

Powered By GrowthZone